BIOMAT Database Logo BIOMAT Database Logo

Benefits, harms, and costs of newborn genetic screening for hypertrophic cardiomyopathy: Estimates from the PreEMPT model. 2023

Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Department of Population Medicine, Harvard Medical School, Boston, MA; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA. Electronic address: kurt_christensen@harvardpilgrim.org.

Population newborn genetic screening for hypertrophic cardiomyopathy (HCM) is feasible, however its benefits, harms, and cost-effectiveness are uncertain. We developed a microsimulation model to simulate a US birth cohort of 3.7 million newborns. Those identified with pathogenic/likely pathogenic variants associated with increased risk of HCM underwent surveillance and recommended treatment, whereas in usual care, individuals with family histories of HCM underwent surveillance. In a cohort of 3.7 million newborns, newborn genetic screening would reduce HCM-related deaths through age 20 years by 44 (95% uncertainty interval [UI] = 10-103) however increase the numbers of children undergoing surveillance by 8127 (95% UI = 6308-9664). Compared with usual care, newborn genetic screening costs $267,000 per life year saved (95% UI, $106,000 to $919,000 per life year saved). Newborn genetic screening for HCM could prevent deaths but at a high cost and would require many healthy children to undergo surveillance. This study shows how modeling can provide insights into the tradeoffs between benefits and costs that will need to be considered as newborn genetic screening is more widely adopted.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000094703 Cost-Effectiveness Analysis A method of comparing the cost of a program with its expected outcomes that are qualitative in nature. Cost effectiveness compares alternative ways to achieve a specific set of results. Cost Effectiveness,Cost Effectiveness Ratio,Analysis, Cost-Effectiveness,Cost Effectiveness Analysis,Cost Effectiveness Ratios,Effectiveness Ratio, Cost,Effectiveness, Cost,Ratio, Cost Effectiveness
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015997 Neonatal Screening The identification of selected parameters in newborn infants by various tests, examinations, or other procedures. Screening may be performed by clinical or laboratory measures. A screening test is designed to sort out healthy neonates (INFANT, NEWBORN) from those not well, but the screening test is not intended as a diagnostic device, rather instead as epidemiologic. Infant, Newborn, Screening,Newborn Infant Screening,Newborn Screening,Neonatal Screenings,Newborn Infant Screenings,Newborn Screenings,Screening, Neonatal,Screening, Newborn,Screening, Newborn Infant,Screenings, Neonatal,Screenings, Newborn,Screenings, Newborn Infant
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults

Related Publications

Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Screening children at risk for hypertrophic cardiomyopathy: balancing benefits and harms.
December 2019, European heart journal,
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.
November 2009, Annals of internal medicine,
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.
February 2017, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.
July 2015, Journal of the National Cancer Institute,
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs.
June 2022, Cancers,
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Maximizing Benefits and Minimizing Harms: Diagnostic Uncertainty Arising From Newborn Screening.
December 2021, Pediatrics,
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.
July 2014, Annals of internal medicine,
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Genetic testing for familial hypertrophic cardiomyopathy in newborn infants.
April 1995, BMJ (Clinical research ed.),
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
Genetic analysis for predictive screening in hypertrophic cardiomyopathy.
April 2012, Heart (British Cardiac Society),
Kurt D Christensen, and Pamela M McMahon, and Lauren N Galbraith, and Jennifer M Yeh, and Natasha K Stout, and Christine Y Lu, and Sarah Stein, and Maryann Zhao, and Robyn J Hylind, and Ann Chen Wu
On the benefits and costs of genetic screening.
March 1978, American journal of human genetics,
Copied contents to your clipboard!